Advancing Cancer Therapies: The Role of Phase I Clinical Trials

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 50 Minutes

Overview

Participants will investigate the comprehensive domain of phase I clinical trials in cancer therapy, highlighting their critical role in advancing treatment options through the evaluation of new drugs and dosing strategies. The session will focus on differentiating among various trial designs and their pivotal roles in modern oncology drug development. Additionally, the complexities of patient eligibility and trial navigation will be addressed, emphasizing the challenges these factors pose in patient management and care.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

  1. Identify the key elements of oncology phase I clinical trials, including trial purpose, primary objective, and endpoints
  2. Outline general design concepts for phase I clinical trials
  3. Describe the U.S. Food and Drug Administration (FDA) initiatives emphasized in modern phase I clinical trials, including Project Optimus and Project FrontRunner
  4. Review strategies the advanced practice providers can employ to help patients access and navigate clinical trials in the community setting 
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course opens: 
09/05/2025
Course expires: 
09/05/2026
Cost:
$0.00
Rating: 
0

Faculty

Justin Call, MD

Director of Clinical Research
START Mountain Region
Utah Cancer Specialists
West Valley City, UT

Dr. Justin Call, is the Director of Clinical Research at START Mountain Region in Salt Lake City, Utah. He received his undergraduate degree from the University of Utah, and his medical degree from the University of Colorado Health Sciences Center in Denver, Colorado. During his academic training, Dr. Call was elected to numerous honor societies, including the Golden Key Honor Society, Phi Kappa Phi Honor Society, and the Alpha Omega Alpha Honor Medical Society.  

Dr. Call completed residency training in Internal Medicine and fellowship training in Hematology and Medical Oncology at the University of Colorado Health Sciences Center. He is board certified in Hematology and Medical Oncology. Dr. Call’s clinical interests include drug development of new anticancer agents, with a special interest in gynecologic cancers and hematologic malignancies. He has been the principal investigator / co-investigator of over 50 cancer clinical trials. Dr. Call is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American Association for Cancer Research. 

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Justin Call,  discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.

Available Credit

  • 0.75 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Price

Cost:
$0.00
Please login or register to take this course.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test
  4. Submit the evaluation form

DISCLAIMER:

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above